United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

accord-uk ltd - epirubicin hydrochloride - solution for injection - 2mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

accord-uk ltd - epirubicin hydrochloride - solution for injection - 2mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

accord-uk ltd - epirubicin hydrochloride - solution for injection - 2mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

accord-uk ltd - epirubicin hydrochloride - solution for infusion - 2mg/1ml

United States - English - NLM (National Library of Medicine)

pharmacia & upjohn company llc - epirubicin hydrochloride (unii: 22966tx7j5) (epirubicin - unii:3z8479zz5x) - epirubicin hydrochloride 2 mg in 1 ml - ellence is indicated as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer [see clinical studies (14.1)] . ellence is contraindicated in patients with: risk summary based on findings from animal studies and its mechanism of action, ellence can cause fetal harm when administered to a pregnant woman [see clinical pharmacology (12.1)] ; avoid the use of ellence during the 1st trimester. available human data do not establish the presence or absence of major birth defects and miscarriage related to the use of epirubicin during the 2nd and 3rd trimesters. there are reports of fetal and/or neonatal cardiotoxicity following in utero exposure to epirubicin (see error! hyperlink reference not valid. ). in animal reproduction studies in pregnant rats, epirubicin was embryo-fetal lethal and caused structural abnormalities when administered during organogenesis at doses less than the maximum recommended human dose on a body surface

Israel - English - Ministry of Health

inovamed ltd - epirubicin hydrochloride - solution for injection - epirubicin hydrochloride 2 mg / 1 ml - epirubicin - epirubicin - for the treatment of wide spectrum of neoplastic diseases including breast carcinoma, lung carcinoma high doses, ovarian carcinoma, gastric carcinomas, soft tissue sarcoma. intravesical administration of epirubicin has been found to be beneficial in the treatment of superficial bladder carcinomas and in the prophylaxis of recurrences after transurethral resection. i.v. administration for the treatment of advanced bladder carcinoma.

Namibia - English - Namibia Medicines Regulatory Council

sandoz sa (pty) ltd - epirubicin - solution for infusion - each 100ml solution contains epirubicin hydrochloride 200,0 mg

Namibia - English - Namibia Medicines Regulatory Council

sandoz sa (pty) ltd - epirubicin - solution for infusion - each 50ml solution contains epirubicin hydrochloride 100,0 mg

Israel - English - Ministry of Health

novartis israel ltd - epirubicin hydrochloride - concentrate for solution for infusion - epirubicin hydrochloride 2 mg/ml - epirubicin - for the treatment of wide spectrum of neoplastic diseases including breast carcinoma, lung carcinoma (high doses), ovarian carcinoma, gastric carcinomas, soft tissue sarcoma. intravesical administration of farmorubicin has been found to be beneficial in the treatment of superficial bladder carcinomas and in the prophylaxis of recurrences after stransurethral resection. i.v. administration for the treatment of advanced bladder carcinoma.

Canada - English - Health Canada

pfizer canada ulc - epirubicin hydrochloride - solution - 2mg - epirubicin hydrochloride 2mg - antineoplastic agents